Intraluminal Support Device LVIS/LVIS Jr./LVIS EVO
Microvention, Inc. · Decision date Sep 16, 2026
What did the FDA decide?
The FDA record shows a 30-day notice for P170013/S013, supplement reason listed as process change affecting manufacturer, sterilizer, packager or supplier. The stated purpose is to add automated robotic arms to the existing pickling and etching manufacturing processes for the LVIS/LVIS Jr./LVIS EVO intraluminal support device. The identifier ties this to PMA P170013, but the record is a supplement, not a new approval of the whole system, and it is a manufacturing notice rather than an original PMA.
The notice does not specify which manufacturing site is affected, the pickling or etching parameters involved, how the robotic arms integrate with existing steps, or what validation data were submitted. Nothing in the supplied fields reports safety or clinical effectiveness findings; the stated purpose of the change is distinct from proof of those outcomes.
The product is listed under product code QCA in the intracranial coil-assist stent category, with neurology as the specialty and MicroVention, Inc. as applicant.
FDA approval order statement
to add automated robotic arms to the existing pickling and etchingmanufacturing processes
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Neurology
- Decision date
- Sep 16, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P170013/S013
- Regulatory pathway
- PMA supplement
- Applicant
- Microvention, Inc.
- Product code
- QCA
- Decision code
- OK30
- Decision date
- Sep 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Intracranial coil-assist stent.
- Applicant
- Microvention, Inc.
- Product code
- QCA
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P170013. Subsequent supplements may change the device or its indications.
FDA decision timeline
P170013 · Original PMA
Low-Profile Visualized Intraluminal Support (LVIS) and LVIS Jr.
P170013/S013 received
Application receipt date recorded by FDA.
P170013/S013 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P170013. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P170013
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Microvention, Inc. | PMA approval | May 30, 2018 | FDA |
Explore the linked device profile
Other records with product code QCA
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Neuroform Atlas Stent SystemP180031/S012 | Stryker Neurovascular | PMA supplement | Oct 24, 2026 | FDA |
Neuroform Atlas Stent SystemP180031 | Stryker Neurovascular | PMA approval | May 16, 2019 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Microvention, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 35 Enterprise, Aliso Viejo, CA, 92656
Sources and methodology
- Original FDA record: P170013/S013
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
